Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns

Cancer Research

Volumn 72, Issue 22, 2012, Pages 5663-5668

  Singh, Sanjay ^a   Sharma, Arati ^a   Robertson, Gavin P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOCARRIER; NANOCOATING; NANOPARTICLE;

CANCER RESEARCH; CHEMICAL COMPOSITION; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; MOLECULARLY TARGETED THERAPY; NANOCHEMISTRY; NANOPHARMACEUTICS; NANOTOXICOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; NEOPLASMS;

EID: 84869232766     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1527     Document Type: Review

References (53)

1. Langer R. Drug delivery and targeting. Nature 1998;392:5-10.
2. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60.
3. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005;78:585-94.
4. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn 2006;6:307-18.
5. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
6. Aryal S, Hu CM, Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm 2011;8:1401-7.
7. Khdair A, Handa H, Mao G, Panyam J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro . Eur J Pharm Biopharm 2009;71:214-22.
8. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 2008;14:3571-81.
9. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-71.
10. Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 2011;6:e24374.
11. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, et al. Size-dependent cytotoxicity of gold nanoparticles. Small 2007;3:1941-9.
12. Keelan JA. Nanotoxicology: nanoparticles versus the placenta. Nat Nanotechnol 2011;6:263-4.
13. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012;52:481-503.
14. Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1992;1104:95-101.
15. Moreira JN, Gaspar R, Allen TM. Targeting stealth liposomes in a murine model of human small cell lung cancer. Biochim Biophys Acta 2001;1515:167-76.
16. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002;23:1553-61.
17. Chithrani BD, Ghazani AA, Chan WCW. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006;6:662-8.
18. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 2006;114:343-7.
19. Hauck TS, Ghazani AA, Chan WCW. Assessing the effect of surface chemistry on gold nanorod uptake, toxicity, and gene expression in mammalian cells. Small 2008;4:153-9.
20. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 2003;4:11-8.
21. Chen J, Glaus C, Laforest R, Zhang Q, Yang M, Gidding M, et al. Gold nanocages as photothermal transducers for cancer treatment. Small 2010;6:811-7.
22. von Maltzahn G, Park J-H, Agrawal A, Bandaru NK, Das SK, Sailor MJ, et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res 2009;69:3892-900.
23. Murphy CJ, Gole AM, Stone JW, Sisco PN, Alkilany AM, Goldsmith EC, et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res 2008;41:1721-30.
24. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008;3:133-49.
25. Richards D, Ivanisevic A. Inorganic material coatings and their effect on cytotoxicity. Chem Soc Rev 2012;41:2052-60.
26. Voinov MA, Sosa Pagan JO, Morrison E, Smirnova TI, Smirnov AI. Surface-mediated production of hydroxyl radicals as a mechanism of iron oxide nanoparticle biotoxicity. J Am Chem Soc 2011;133:35-41.
27. Hardman R. A toxicologic reviewof quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 2006;114:165-72.
28. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotech 2004;22:969-76.
29. Ow H, Larson DR, Srivastava M, Baird BA, Webb WW, Wiesner U. Bright and stable core-shell fluorescent silica nanoparticles. Nano Lett 2005;5:113-7.
30. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008;5:487-95.
31. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297-315.
32. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012;7:49-60.
33. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009;26:523-80.
34. Patel HM, Moghimi SM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-The concept of tissue specificity. Adv Drug Deliv Rev 1998;32:45-60.
35. Benvegnu T, Lemiegre L, Cammas-Marion S. New generation of liposomes called archaeosomes based on natural or synthetic archaeal lipids as innovative formulations for drug delivery. Recent Pat Drug Deliv Formul 2009;3:206-20.
36. Fang J, Sawa T, Maeda H, Kabanov A, Kataoka K, Okano T. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS polymer drugs in the clinical stage. Springer US; 2004. p. 29-49.
37. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24.
38. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51.
39. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-46.
40. Singh N, Karambelkar A, Gu L, Lin K, Miller JS, Chen CS, et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. J Am Chem Soc 2011;133:19582-5.
41. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148:135-46.
42. Zellmer S, Cevc G. Tumor targeting in vivo by means of thermolabile fusogenic liposomes. J Drug Target 1996;4:19-29.
43. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 2012;4:330-42.
44. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-57.
45. Cao Z, Tong R, Mishra A, Xu W, Wong GC, Cheng J, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl 2009;48:6494-8.
46. Brumlik MJ, Daniel BJ, Waehler R, Curiel DT, Giles FJ, Curiel TJ. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. Expert Opin Drug Deliv 2008;5:87-103.
47. Olsnes S, Klingenberg O, Wiedlocha A. Transport of exogenous growth factors and cytokines to the cytosol and to the nucleus. Physiol Rev 2003;83:163-82.
48. Mach J-P. Tumours: targeting of monoclonal antibodies for imaging and potential for therapy. eLS: John Wiley & Sons, Ltd; 2002. p. 1-13.
49. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70.
50. Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest 2011;121:2768-80.
51. Cho YW, Park JH, Park JS, Park K, Gad SC. Pegylation: camouflage of proteins, cells, and nanoparticles against recognition by the body's defense mechanism. Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing. John Wiley & Sons, Inc.; 2007. p. 443-57.
52. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995;17:31-48.
53. Jeon SI, Andrade JD. Protein surface interactions in the presence of polyethylene oxide: II. Effect of protein size. J Colloid Interface Sci 1991;142:159-66.